PLK4

Serine/threonine-protein kinase PLK4

155,526 patent compounds predicted against PLK4, 118,389 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Linifanib (SCHEMBL93804)	1.00	4/20
SCHEMBL58313	0.59	3/20
SCHEMBL58543	0.57	3/20
SCHEMBL60464	0.57	3/20
SCHEMBL58550	0.55	3/20
SCHEMBL19433	0.55	3/20
SCHEMBL59884	0.54	3/20
SCHEMBL65790	0.52	3/20
Hydrochloric Acid (SCHEMBL58421)	0.52	3/20
SCHEMBL62264	0.51	3/20
SCHEMBL20114	0.50	3/20
SCHEMBL21480	0.50	3/20
SCHEMBL58416	0.50	3/20
SCHEMBL59547	0.49	3/20
SCHEMBL60289	0.48	3/20
SCHEMBL58735	0.47	3/20
SCHEMBL20497	0.46	3/20
SCHEMBL60366	0.45	3/20
SCHEMBL20604	0.43	3/20
Alvocidib (SCHEMBL3651)	1.00	2/20

Germline variants in PLK4 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full PLK4 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to PLK4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor	PHASE2	ACTIVE_NOT_RECRUITING
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer	PHASE2	COMPLETED
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer	PHASE2	COMPLETED
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer	PHASE2	COMPLETED
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype	PHASE2	RECRUITING
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma	PHASE1/PHASE2	COMPLETED
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer	PHASE2	RECRUITING
A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression	PHASE2	COMPLETED
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors	PHASE1/PHASE2	COMPLETED
Protein Tyrosine Kinases (PTK) in Multiple Myeloma	PHASE2	COMPLETED
Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome	PHASE2	WITHDRAWN
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia	PHASE2	COMPLETED
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	PHASE1	COMPLETED
Study of ABT-751 in Patients With Refractory Hematologic Malignancies	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer	PHASE1	ACTIVE_NOT_RECRUITING
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry	nan	RECRUITING
Implementing Patients´ Competence in Oral Breast Cancer Therapy	nan	UNKNOWN
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Impact of Weight Loss on the Human Sperm Epitranscriptome	nan	ACTIVE_NOT_RECRUITING
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies	nan	ENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a PLK4 binder may also engage these)

Protein	Name	Similarity
A2VDZ4	—	1.000	A2VDZ4 →
Q5R9Z7	—	1.000	Q5R9Z7 →
B2GUY1	—	1.000	B2GUY1 →
Q6PAD2	—	1.000	Q6PAD2 →
A7SNN5	—	1.000	A7SNN5 →
O97143	—	1.000	O97143 →
Q2LYK3	—	1.000	Q2LYK3 →
B4HBU3	—	0.999	B4HBU3 →
B3DL84	—	0.998	B3DL84 →
B4QK53	—	0.997	B4QK53 →
B4LDJ6	—	0.997	B4LDJ6 →
Q64702	—	0.997	Q64702 →
B3M6I4	—	0.996	B3M6I4 →
Q7ZVS3	—	0.996	Q7ZVS3 →
Q2QMH1	—	0.995	Q2QMH1 →
A6ZZF6	—	0.995	A6ZZF6 →
B3NE99	—	0.994	B3NE99 →
B4PDM5	—	0.994	B4PDM5 →
B4J3F1	—	0.994	B4J3F1 →
Q0WPH8	—	0.994	Q0WPH8 →
Q12310	—	0.994	Q12310 →
Q74ZH7	—	0.994	Q74ZH7 →
A2QHV0	—	0.994	A2QHV0 →
Q75CH3	—	0.994	Q75CH3 →
B4IAQ8	—	0.994	B4IAQ8 →
Q9Y7T4	—	0.993	Q9Y7T4 →
O43078	—	0.993	O43078 →
P13185	—	0.993	P13185 →
B4KYX8	—	0.992	B4KYX8 →
P83102	—	0.992	P83102 →